CEMI - Chembio Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.10
+0.13 (+1.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.87
Open6.90
Bid6.95 x 3100
Ask12.35 x 900
Day's Range6.80 - 7.10
52 Week Range4.39 - 10.79
Volume66,898
Avg. Volume40,887
Market Cap124.715M
Beta (3Y Monthly)1.76
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors, one of the world’s leading healthcare-focused investment firms. “We are excited to have received this capital from Perceptive Advisors, a prestigious and well-regarded healthcare investment firm.” said John Sperzel, Chembio’s Chief Executive Officer.

  • GlobeNewswire

    Chembio Diagnostics to Participate in Upcoming Investor Conferences

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences. Management is scheduled to participate in the Dougherty & Company Institutional Investor Conference in Minneapolis, Minnesota on Thursday, September 5, 2019. Management is also scheduled to present at the Janney Healthcare Conference in New York, New York on Monday, September 9, 2019 at 12:35 pm ET.

  • GlobeNewswire

    Chembio Diagnostics Reports Second Quarter 2019 Financial Results

    MEDFORD, N.Y., Aug. 06, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics to Participate in the Canaccord Genuity Growth Conference

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.

  • GlobeNewswire

    Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.

  • GlobeNewswire

    Chembio Diagnostics and Takeda Pharmaceutical Company Enter Collaboration to Develop Point-of-Care Diagnostic Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that it has entered into a collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global pharmaceutical company, to develop a novel POC diagnostic test to detect an undisclosed biomarker. Under terms of the agreement, Chembio will receive funding from Takeda, subject to satisfying certain milestones, to develop a quantitative POC test utilizing Chembio’s patented DPP platform and hand-held optical analyzer. The development of the POC test will build upon Takeda’s technical research on a unique set of biomarkers and is expected to provide quantitative results in approximately 15 minutes from a small 10µL drop of fingerstick blood.

  • GlobeNewswire

    Chembio Diagnostics Receives CE Mark for its Point-of-Care Multiplex Test for Zika, Dengue and Chikungunya

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • GlobeNewswire

    Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of antibodies against all four dengue serotypes for both active infection by dengue virus (IgM) and prior exposure to the dengue virus (IgG), which is important for both treatment and surveillance.

  • GlobeNewswire

    Chembio Diagnostics Reports First Quarter 2019 Financial Results

    MEDFORD, N.Y., May 01, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics to Report First Quarter 2019 Financial Results on May 1, 2019

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Wednesday, May 1, 2019. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

  • GlobeNewswire

    Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Zika/Dengue/Chikungunya System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos/Fiocruz. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • GlobeNewswire

    Chembio Diagnostics Announces Agreement with Perseus Science to Advance Point-of-Care Concussion Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the company has entered into an agreement with Perseus Science Group LLC, to advance the development of a diagnostic test for mild traumatic brain injury (TBI), or concussion. This agreement builds on previous agreements between the two firms that resulted in the completion of technical feasibility to detect Perseus’ patented biomarker. Under terms of this agreement, Chembio will receive funding from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion, combining Chembio's proprietary DPP platform with Perseus’ biomarker.

  • GlobeNewswire

    Chembio Diagnostics Reports Fourth Quarter and Full Year 2018 Financial Results

    MEDFORD, N.Y., March 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics Awarded UNICEF Contract to Supply Point-of-Care Zika/Chikungunya/Dengue Tests and Micro Readers

    Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced that it will be awarded a conditional Long Term Arrangement (LTA) from UNICEF for purchases of the company’s DPP® Zika/Chikungunya/Dengue System. The UNICEF LTA, which is valid through December 31, 2020, includes a firm purchase commitment of $1.5 million and possible additional purchases of up to $2.0 million, for a total amount of up to $3.5 million. All of the purchases are subject to Chembio meeting the following conditions: receipt of CE mark certification, completion of clinical and analytical performance evaluation, and a successful quality management system (QMS) inspection.

  • GlobeNewswire

    Chembio Diagnostics to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2018 after the close of trading on Thursday, March 7, 2019. Chembio Diagnostics, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The Company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

  • GlobeNewswire

    Chembio Diagnostics to Participate in the BTIG Medical Technology, Life Science and Diagnostic Tools Conference

    MEDFORD, N.Y., Feb. 19, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.

  • GlobeNewswire

    Chembio Diagnostics Reports Preliminary Fourth Quarter and Full Year 2018 Revenue

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today preliminary estimates of revenue for the fourth quarter and full year 2018, as well as long-term strategic targets. Revenue for the fourth quarter of 2018 is expected to be between $7.3 million and $7.6 million, an increase of approximately 22% to 27% compared to the fourth quarter of 2017. As a result, there is a possibility that final revenue results will not be within the ranges Chembio currently estimates.  The company undertakes no responsibility to update its revenue outlook.

  • GlobeNewswire

    Chembio Diagnostics Announces 2019 Analyst and Investor Meeting

    MEDFORD, N.Y., Jan. 17, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.

  • GlobeNewswire

    Chembio Diagnostics Receives CE Mark for Point-of-Care Diagnostic Test  Developed in Collaboration with AstraZeneca

    MEDFORD, N.Y., Jan. 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it.

  • GlobeNewswire

    Chembio’s French Partner AAZ-LMB Wins Prix Galien International for Best Medical Technology with autotest VIH®

    MEDFORD, N.Y., Dec. 06, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that its.

  • GlobeNewswire

    Factors of Influence in 2018, Key Indicators and Opportunity within Sun Hydraulics, FIS, TRACON Pharmaceuticals, Kona Grill, Endava PLC Sponsored ADR, and Chembio Diagnostics — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire

    Chembio Ebola Virus Diagnostic Test Receives U.S. FDA Emergency Use Authorization

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care ("POC") diagnostics company focused on infectious diseases, today announced the receipt of U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its DPP® Ebola Antigen System for use with human capillary “fingerstick” whole blood, EDTA venous whole blood, and EDTA plasma. The DPP® Ebola Antigen System includes the DPP® Ebola Assay and DPP® Micro Reader.

  • GlobeNewswire

    Chembio to Participate in Upcoming Investor Conferences

    MEDFORD, N.Y., Nov. 09, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced plans to.

  • GlobeNewswire

    Chembio Diagnostics Reports Third Quarter 2018 Financial Results

    MEDFORD, N.Y., Nov. 08, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics Announces Pricing of its Public Offering of Common Stock

    Chembio Diagnostics, Inc. (CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today the pricing of its previously announced underwritten registered public offering of 2,370,435 shares of its common stock at a public offering price of $6.75 per share for gross proceeds of approximately $16.0 million. In addition, Chembio has granted the underwriter a 30-day option to purchase up to an additional 355,565 shares of common stock.  All shares of common stock to be sold in the offering will be offered by Chembio.